EGFR T790M
genetic variant
üksikjuht nähtusest
chromosome
genomic start
genomic end
biological variant of
positive therapeutic predictor for
määramismeetod: CIViC evidence level B
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 4-star trust rating
määramismeetod: CIViC evidence level E
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 1-star trust rating
määramismeetod: CIViC evidence level D
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 3-star trust rating
määramismeetod: CIViC evidence level B
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 4-star trust rating
määramismeetod: CIViC evidence level B
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 3-star trust rating
määramismeetod: CIViC evidence level D
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 3-star trust rating
määramismeetod: CIViC evidence level A
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 5-star trust rating
määramismeetod: CIViC evidence level C
medical condition treated: adenocarcinoma of the lung
rating: CIViC 1-star trust rating
määramismeetod: CIViC evidence level C
medical condition treated: adenocarcinoma of the lung
rating: CIViC 2-star trust rating
määramismeetod: CIViC evidence level D
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 2-star trust rating
määramismeetod: CIViC evidence level D
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 2-star trust rating
määramismeetod: CIViC evidence level D
medical condition treated: non-small-cell lung carcinoma
rating: CIViC 2-star trust rating
rating: CIViC 3-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level C
rating: CIViC 2-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level D
rating: CIViC 2-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level D
rating: CIViC 3-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level D
määramismeetod: CIViC evidence level C
rating: CIViC 2-star trust rating
medical condition treated: pancreatic adenocarcinoma
statement disputed by: EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
negative therapeutic predictor for
rating: CIViC 5-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level A
rating: CIViC 3-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level B
rating: CIViC 4-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level B
rating: CIViC 3-star trust rating
medical condition treated: adenocarcinoma of the lung
määramismeetod: CIViC evidence level B
rating: CIViC 3-star trust rating
medical condition treated: adenocarcinoma of the lung
määramismeetod: CIViC evidence level B
rating: CIViC 3-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level B
rating: CIViC 4-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level B
rating: CIViC 4-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level D
rating: CIViC 4-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level C
rating: CIViC 4-star trust rating
medical condition treated: non-small-cell lung carcinoma
määramismeetod: CIViC evidence level C
Viited
- ↑ CIViC database
- ↑ 2,00 2,01 2,02 2,03 2,04 2,05 2,06 2,07 2,08 2,09 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/variants/34
- ↑ OpenAlex, 26. jaanuar 2022, https://docs.openalex.org/download-snapshot/snapshot-data-format
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/646, Rociletinib in EGFR-mutated non-small-cell lung cancer
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/278, A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/963, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/965, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/966, Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/762, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1592, Osimertinib: First Global Approval
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1867, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1397, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2157, EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2162, Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2163, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2164, Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2165, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/277, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
- ↑ 19,0 19,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/967, In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2161, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/6006, EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/238, EGFR T790M resistance mutation in non small-cell lung carcinoma
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/239, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
- ↑ 24,0 24,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1667, Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/240, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
- ↑ 26,0 26,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1391, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1863, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2160, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- ↑ 29,0 29,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2158, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/369, The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
- ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/370, Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients